Functional consequence of serotonin/5-HT2B receptor signaling in heart: Role of mitochondria in transition between hypertrophy and heart failure?

Circulation

Volumn 108, Issue 7, 2003, Pages 902-908

  Nebigil, Canan G ^b   Maroteaux, Luc ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b NONE

Author keywords

Cardiomyopathy; Genetics; Hypertrophy; Receptors; Signal transduction

Indexed keywords

SEROTONIN; SEROTONIN 2B RECEPTOR;

EMBRYO DEVELOPMENT; HEART DILATATION; HEART FAILURE; HEART HYPERTROPHY; HEART MITOCHONDRION; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART FAILURE, CONGESTIVE; HUMANS; MICE; MICE, KNOCKOUT; MITOCHONDRIA, HEART; MYOCARDIUM; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTORS, SEROTONIN; SIGNAL TRANSDUCTION;

EID: 0042934294     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000081520.25714.D9     Document Type: Review

References (49)

1. Villalon CM, de Vries P, Saxena PR. Serotonin receptors as cardiovascular targets. Drug Discov Today. 1997;2:294-300.
2. Frishman WH, Grewall P. Serotonin and the heart. Ann Med. 2000;32:195-209.
3. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71:533-554.
4. Nebigil CG, Launay J-M, Hickel P, et al. 5-Hydroxytryptamine 2B receptor regulates cell-cycle progression: cross talk with tyrosine kinase pathways. Proc Natl Acad Sci U S A. 2000;97:2591-2596.
5. Nebigil CG, Etienne N, Schaerlinger B, et al. Developmentally regulated serotonin 5-HT2B receptors. Int J Dev Neurosci. 2001;19:365-372.
6. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995;92:790-795.
7. Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med. 1997;102:54-59.
8. Musselman DL, Nemeroff CB. Depression really does hurt your heart: stress, depression, and cardiovascular disease. Prog Brain Res. 2000;122:43-59.
9. Badon LA, Hicks A, Lord K, et al. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. J Pharmacol Exp Ther. 2002;302:898-907.
10. Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther. 2002;95:73-88.
11. Xu J, Jian B, Chu R, et al. Serotonin mechanisms in heart valve disease II: the 5-HT(2) receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol. 2002;161:2209-2218.
12. Launay JM, Hervé P, Peoc'h K, et al. Role of serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002;8:1129-1135.
13. Nebigil CG, Choi D-S, Dierich A, et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A. 2000;97:9508-9513.
14. Offermanns S, Zhao LP, Gohla A, et al. Embryonic cardiomyocyte hypoplasia and craniofacial defects in Gαq/Gα11-mutant mice. EMBO J. 1998;17:4304-4312.
15. Nebigil CG, Hickel P, Messaddeq N, et al. Ablation of serotonin 5-HT2B receptors in mice leads to abnormal cardiac structure and function. Circulation 2001;103:2973-2979.
16. Schaper J, Froede R, Hein S, et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation. 1991;83:504-514.
17. Beltrami CA, Finato N, Rocco M, et al. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol. 1995;27:291-305.
18. Radice GL, Rayburn H, Matsunami H, et al. Developmental defects in mouse embryos lacking N-cadherin. Dev Biol. 1997;181:64-78.
19. Wang X, Gerdes AM. Chronic pressure overload cardiac hypertrophy and failure in guinea pigs. III: intercalated disc remodeling. J Mol Cell Cardiol. 1999;31:333-343.
20. 2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation. 2003;107:3223-3229.
21. Takeishi Y, Ping P, Bolli R, et al. Transgenic overexpression of constitutively active protein kinase Cε causes concentric cardiac hypertrophy. Circ Res. 2000;86:1218-1223.
22. Bowman JC, Steinberg SF, Jiang T, et al. Expression of protein kinase Cβ in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest. 1997;100:2189-2195.
23. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000;19:6341-6350.
24. Paradis P, Dali-Youcef N, Paradis FW, et al. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A. 2000;97:931-936.
25. Harada K, Sugaya T, Murakami K, et al. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation. 1999;100:2093-2099.
26. Milano CA, Dolber PC, Rockman HA, et al. Myocardial expression of a constitutively active α1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci U S A. 1994;91:10109-10113.
27. Akhter SA, Milano CA, Shotwell KF, et al. Transgenic mice with cardiac overexpression of α1B-adrenergic receptors: in vivo α1-adrenergic receptor-mediated regulation of β-adrenergic signaling. J Biol Chem. 1997;272:21253-21259.
28. Wettschureck N, Rutten H, Zywietz A, et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes. Nat Med. 2001;7:1236-1240.
29. Towbin JA, Bowles NE. The failing heart. Nature. 2002;415:227-233.
30. Chien KR, Olson EN. Converging pathways and principles in heart development and disease: CV@CSH. Cell. 2002;110:153-162.
31. Nebigil CG, Etienne N, Messaddeq N, et al. Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a direct of 5-HT2B-receptor signaling. FASEB J. 2003;17:1373-1375.
32. Narula J, Kolodgie FD, Virmani R. Apoptosis and cardiomyopathy. Curr Opin Cardiol. 2000;15:183-188.
33. Reed JC, Paternostro G. Postmitochondrial regulation of apoptosis during heart failure. Proc Natl Acad Sci U S A. 1999;96:7614-7616.
34. Communal C, Sumandea M, de Tombe P, et al. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci U S A. 2002;99:6252-6256.
35. Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol. 2001;2:67-71.
36. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479-489.
37. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
38. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999;13:239-252.
39. Suleiman MS, Halestrap AP, Griffiths EJ. Mitochondria: a target for myocardial protection. Pharmacol Ther. 2001;89:29-46.
40. Vieira HL, Haouzi D, El Hamel C, et al. Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator. Cell Death Differ. 2000;7:1146-1154.
41. Portman MA. The adenine nucleotide translocator: regulation and function during myocardial development and hypertrophy. Clin Exp Pharmacol Physiol. 2002;29:334-338.
42. Domer A, Schultheiss HP. The myocardial expression of the adenine nucleotide translocator isoforms is specifically altered in dilated cardiomyopathy. Herz. 2000;25:176-180.
43. Graham BH, Waymire KG, Cottrell B, et al. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet. 1997;16:226-234.
44. Kaukonen J, Juselius JK, Tiranti V, et al. Role of adenine nucleotide translocator I in mtDNA maintenance. Science. 2000;289:782-785.
45. Bauer MK, Schubert A, Rocks O, et al. Adenine nucleotide translocase-1, a component of the permeability transition pore, can dominantly induce apoptosis. J Cell Biol. 1999;147:1493-1502.
46. Akyurek O, Akyurek N, Sayin T, et al. Association between the severity of heart failure and the susceptibility of myocytes to apoptosis in patients with idiopathic dilated cardiomyopathy. Int J Cardiol. 2001;80:29-36.
47. Chien KR. Genomic circuits and the integrative biology of cardiac diseases. Nature. 2000;407:227-232.
48. Wallace DC. Mitochondrial defects in cardiomyopathy and neuromuscular disease. Am Heart J. 2000;139:S70-S85.
49. Yussman MG, Toyokawa T, Odley A, et al. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med. 2002;8:725-730.